siRNA as a new drug: intellectual property

Author： Schiffelers Raymond M   van Kolfschoten Sarianne C   van Dijk Maarten   Scaria Putthupparampil V   Woodle Martin C   Storm Gert  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.15, Iss.2, 2005-02, pp. : 141-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RNAi and siRNA

By Jain KK  

Pharmacogenomics, Vol. 5, Iss. 3, 2004-04 ,pp. : 239-242

Future Medicine

Access to resources Recommend Favorite

Intellectual property rights helping limit drug accessibility

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 581, 2009-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

The Development and Mechanism Studies of Cationic Chitosan-Modified Biodegradable PLGA Nanoparticles for Efficient siRNA Drug Delivery

By Yuan Xudong   Shah Bruhal   Kotadia Naimesh   Li Jian   Gu Hua   Wu Zhiqian  

Pharmaceutical Research, Vol. 27, Iss. 7, 2010-07 ,pp. : 1285-1295

Springer Publishing Company

Access to resources Recommend Favorite

Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity

By Hollins Andrew   Omidi Yadollah   Benter Ibrahim   Akhtar Saghir  

Journal of Drug Targeting, Vol. 15, Iss. 1, 2007-01 ,pp. : 83-88

Informa Healthcare

Access to resources Recommend Favorite

Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy

By  

Current Drug Delivery, Vol. 13, Iss. 7, 2016-10 ,pp. : 1176-1182

Bentham Science Publishers

Access to resources Recommend Favorite